1h Free Analyst Time
The Drug Eluting Balloon Market grew from USD 965.84 million in 2023 to USD 1.09 billion in 2024. It is expected to continue growing at a CAGR of 15.51%, reaching USD 2.65 billion by 2030. Speak directly to the analyst to clarify any post sales queries you may have.
The Drug Eluting Balloon (DEB) is a medical device used primarily in cardiovascular interventions, specifically to deliver a drug locally to the arterial wall while also addressing vascular occlusion. Unlike traditional angioplasty balloons, DEBs offer the dual benefit of physically expanding blocked arteries while releasing antiproliferative drugs to minimize restenosis. The necessity of DEBs arises from the high prevalence of coronary artery disease and peripheral artery disease, conditions where minimizing the risk of restenosis is crucial. DEBs find application in the treatment of in-stent restenosis, small vessel disease, and bifurcation lesions and are often used in conjunction with other interventional devices to improve patient outcomes. End-use scope includes hospitals, ambulatory surgical centers, and specialist cardiac care facilities.
Market growth is propelled by the increasing geriatric population, the rising incidence of cardiovascular disorders globally, and technological advancements in interventional cardiology. Key potential opportunities include expanding the geographical footprint of DEB products into emerging markets with growing healthcare infrastructure and investing in R&D to enhance efficacy and safety profiles. Innovative opportunities exist in developing DEBs with biodegradable materials and synergistic drug compositions that further boost re-endothelialization.
However, market growth faces challenges such as stringent regulatory requirements, the high cost of DEBs, and competition from alternative treatments like drug-eluting stents or bypass graft surgery. Integrating artificial intelligence and machine learning into patient-specific treatment protocols represents an innovative growth area, potentially improving patient outcomes by customizing drug dosage and delivery. Lastly, while the DEB market remains promising, it is essential to address its limitations through continued clinical trials and real-world studies to validate long-term benefits and safety, thus widening their acceptance in mainstream clinical practice. By focusing on technological enhancements and strategic global market penetration, companies can harness significant growth in this dynamic field.
Understanding Market Dynamics in the Drug Eluting Balloon Market
The Drug Eluting Balloon Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.- Market Drivers
- Increasing Geriatric Population Leading to Cardiovascular Diseases
- Rising Prevalence of Peripheral and Coronary Artery Diseases
- Favorable Approvals to Support the Growth of DEBs
- Market Restraints
- Issues Associated to Product Recalls of Drug-Eluting Balloons
- Market Opportunities
- New Developments in the Clinical Use of Drug-Coated Balloon Catheters
- Advancement, Innovation, and Research in Drug-Coated Balloons
- Market Challenges
- Lack of Availability for Skilled and Trained Professionals
Exploring Porter’s Five Forces for the Drug Eluting Balloon Market
Porter’s Five Forces framework further strengthens the insights of the Drug Eluting Balloon Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.Applying PESTLE Analysis to the Drug Eluting Balloon Market
External macro-environmental factors deeply influence the performance of the Drug Eluting Balloon Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.Analyzing Market Share in the Drug Eluting Balloon Market
The Drug Eluting Balloon Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.Evaluating Vendor Success with the FPNV Positioning Matrix in the Drug Eluting Balloon Market
The Drug Eluting Balloon Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.Key Company Profiles
The report delves into recent significant developments in the Drug Eluting Balloon Market, highlighting leading vendors and their innovative profiles. These include Medtronic PLC, Becton, Dickinson and Company, Boston Scientific Corporation, M.A. Med Alliance SA by Cordis Corporation, Eurocor Tech GmbH, Lepu Medical Technology, Invamed, Biotronik SE & Co. KG, Cook Medical, Inc., Terumo Corporation, Cardionovum GmbH, SurModics, Inc., Johnson & Johnson Services, Inc., Balton Sp. z o. o., B. Braun Melsungen AG, Bayer AG, Abbott Laboratories, Wellinq, Laborie Medical Technologies, Inc., Concept Medical, Zylox-Tonbridge Medical Technology Co., Ltd., Biosensors International Group, Ltd., Koninklijke Philips N.V., and iVascular S.L.U..Market Segmentation & Coverage
This research report categorizes the Drug Eluting Balloon Market to forecast the revenues and analyze trends in each of the following sub-markets:- Type
- Coronary Drug Eluting Balloon
- Peripheral Drug Eluting Balloon
- Coating Technology
- EnduraCoat
- FreePac
- Paccocath
- TransPax
- End User
- Ambulatory Surgery Centers
- Cath Labs
- Hospitals
- Region
- Americas
- Argentina
- Brazil
- Canada
- Mexico
- United States
- California
- Florida
- Illinois
- New York
- Ohio
- Pennsylvania
- Texas
- Asia-Pacific
- Australia
- China
- India
- Indonesia
- Japan
- Malaysia
- Philippines
- Singapore
- South Korea
- Taiwan
- Thailand
- Vietnam
- Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom
- Americas
The report provides a detailed overview of the market, exploring several key areas:
- Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
- Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
- Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
- Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
- Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.
Additionally, the report addresses key questions to assist stakeholders in making informed decisions:
- What is the current size of the market, and how is it expected to grow?
- Which products, segments, and regions present the most attractive investment opportunities?
- What are the prevailing technology trends and regulatory factors influencing the market?
- How do top vendors rank regarding market share and competitive positioning?
- What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?
Table of Contents
1. Preface
2. Research Methodology
4. Market Overview
5. Market Insights
6. Drug Eluting Balloon Market, by Type
7. Drug Eluting Balloon Market, by Coating Technology
8. Drug Eluting Balloon Market, by End User
9. Americas Drug Eluting Balloon Market
10. Asia-Pacific Drug Eluting Balloon Market
11. Europe, Middle East & Africa Drug Eluting Balloon Market
12. Competitive Landscape
List of Figures
List of Tables
Companies Mentioned
The leading players in the Drug Eluting Balloon market, which are profiled in this report, include:- Medtronic PLC
- Becton, Dickinson and Company
- Boston Scientific Corporation
- M.A. Med Alliance SA by Cordis Corporation
- Eurocor Tech GmbH
- Lepu Medical Technology
- Invamed
- Biotronik SE & Co. KG
- Cook Medical, Inc.
- Terumo Corporation
- Cardionovum GmbH
- SurModics, Inc.
- Johnson & Johnson Services, Inc.
- Balton Sp. z o. o.
- B. Braun Melsungen AG
- Bayer AG
- Abbott Laboratories
- Wellinq
- Laborie Medical Technologies, Inc.
- Concept Medical
- Zylox-Tonbridge Medical Technology Co., Ltd.
- Biosensors International Group, Ltd.
- Koninklijke Philips N.V.
- iVascular S.L.U.
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 188 |
| Published | October 2024 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 1.09 Billion |
| Forecasted Market Value ( USD | $ 2.65 Billion |
| Compound Annual Growth Rate | 15.5% |
| Regions Covered | Global |
| No. of Companies Mentioned | 25 |
